The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress. The industry has no influence on the content of the programme or speaker selection. All ESMO Colloquia are open to multi-sponsor support and interested sponsors can contact ESMO for more information on future programmes at programme@esmo.org
View the complete ESMO Congress 2021 programme online
Saturday, 18 September 2021
Channel 5
How to optimise efficacy and safety of targeted agent/IO management strategies in advanced solid tumours: Single agents, combinations and biomarkers
18:45 - 20:15 CEST (Central European Summer Time)
This educational activity is provided by ESMO and supported by Eisai Europe Ltd
View the ESMO colloquium details
Learning Objectives
- To provide an update on the efficacy of new combination regimens integrating VEGFR TKIs with immune checkpoint inhibitors in hepatoma, renal and endometrial cancer.
- To provide clinical and molecular decision-making algorithms in order to assist the oncologist in optimal therapeutic choices for their patients among the variety of combination and monotherapy modalities.
- To optimize the proactive and reactive management of side effects with compliance improvement in patients treated with targeted agent/IO combinations.
Monday, 20 September 2021
Channel 3
Multiplex biomarker profiling in contemporary oncology: From testing to understanding and impacting
08:45-10:15 CEST (Central European Summer Time)
This educational activity is provided by ESMO and co-supported by Thermo Fisher Scientific and Eli Lilly
View the ESMO colloquium details
Learning Objectives
- To provide an update on available technologies for multiplex molecular testing and on their recommended uses in clinical practice.
- To provide insights on actionability, evidence for patient benefit from tumour molecular profiling as well as optimal organization of molecular tumour boards.
- To highlight implementation barriers and knowledge gaps related to tumour molecular profiling in practice and propose remedial strategies.